[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Microvention-Terumo, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":156},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,70,112,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100609560","revascularization-in-large-vessel-occlusion-for-acute-ischemic-stroke-100609560",false,"NCT07216170","REVascularization In Large VEssel Occlusion for Acute Ischemic Stroke","REVIVE","Inclusion Criteria:\n\n1. Age ≥18 years on the date of consent\n2. National Institutes of Health Stroke Score (NIHSS) ≥6\n3. Alberta Stroke Program Early CT Score (ASPECTS) ≥6 assessed within 120 minutes before arterial access, defined by either baseline non-contrast computed tomography (NCCT) or baseline diffusion-weighted magnetic resonance imaging (DW-MRI)\n4. Angiographically suitable for endovascular intervention and the interventionalist estimates that arterial access can be achieved within 8 hours from time last known well\n5. Independent status immediately pre-stroke defined as ability to perform all activities of daily living as defined by mRS 0-1\n6. Large vessel occlusion of the intracranial internal carotid artery (ICA), middle cerebral artery (MCA) M1 segment technically accessible, as assessed during the index procedure, using a SOFIA Flow 88 Aspiration Catheter\n7. Subject or legally authorized representative (LAR) is willing and able to provide informed consent, as evidenced by signing and dating the IRB-approved informed consent form prior to initiation of any study-specific procedures\n8. Willing and able to comply with the protocol-specified procedures and assessments\n\nExclusion Criteria:\n\n1. Any intracranial hemorrhage at baseline\n2. Previous stroke within 90 days\n3. Female who is pregnant or lactating or has a positive pregnancy test at time of admission\n4. Arterial occlusive lesion is not technically amenable to recanalization, as assessed during the index procedure, using a SOFIA Flow 88 Aspiration Catheter (e.g., an extracranial carotid lesion prevents access, evidence of carotid dissection)\n5. Clinical symptoms or non-invasive imaging suggestive of or confirming bilateral stroke or stroke in multiple territories defined as multiple large vessel occlusions (e.g., bilateral proximal MCA occlusions)\n6. Comorbid illness that would confound the neurological or functional evaluation or is severe enough (e.g., metastatic cancer, severe congestive heart failure) such that life expectancy is \\\u003C1 year or the 90-day outcome is likely to be determined by the comorbid illness\n7. Any contraindication to endovascular thrombectomy, such as a known history of severe contrast allergy or absolute contraindication to iodinated contrast\n8. Participation in another clinical trial involving an investigational mechanical device (subjects may be co-enrolled in a registry study where there is no investigational treatment).","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this study is to evaluate the safety and effectiveness of the SOFIA Flow 88 Aspiration Catheter for treatment of acute ischemic stroke.",[26],"Acute Ischemic Stroke",[28,29,30,31,32,33,34],"Intracranial large vessel occlusive disease","Revascularization","Large bore catheter","Mechanical thrombectomy","Aspiration","SOFIA®","Direct Aspiration","NOT_YET_RECRUITING","2026-05-21",{"date":38,"type":39},"2026-05-26","ACTUAL",{"date":41,"type":20},"2026-12",{"date":43,"type":20},"2027-12",{"name":45,"class":46},"Microvention-Terumo, Inc.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100641048","phil-middle-meningeal-artery-embolization-for-first-line-treatment-of-chronic-subdural-hematoma-ide-trial-100641048","NCT07576998","PHIL™ Middle Meningeal Artery Embolization for First-Line Treatment of Chronic Subdural Hematoma IDE Trial","PHIL™ (Precipitating Hydrophobic Injectable Liquid) Middle Meningeal Artery Embolization (MMAE) for First-Line Treatment of Chronic Subdural Hematoma (cSDH) IDE Trial (PHILFIRST)","PHILFIRST","Inclusion Criteria:\n\n* Age 22 years or older\n* Diagnosis of chronic subdural hematoma\n* Subject, or their legally authorized representative provides a signed and dated Informed Consent Form\n* Pre-morbid mRS 0-1\n* cSDH measures ≥ 10 mm in greatest thickness\n* cSDH exerts mass effect upon the subjacent brain\n* Imaging characteristics indicative of chronicity\n* Negative urine pregnancy test for female subjects of child-bearing potential\n* Subject is able and willing to comply with all study protocol requirements, including return to the investigational site for all follow-up visits\n* Subject presents with one or more of the following neurological symptoms: headache\u002Fhead pressure, cognitive decline, speech difficulty or aphasia, gait impairment or imbalance, focal neurological deficit (weakness, paresthesia or sensory deficit involving of one or more extremities or facial droop), and\u002For seizure\n\nExclusion Criteria:\n\n* Prior ipsilateral craniotomy or burr hole evacuation of cSDH\n* Prior embolization of either MMA\n* Requires (in the opinion of the treating surgeon) full or mini-craniotomy at time of randomization\n* Emergent subdural hematoma evacuation needed\n* cSDH with a focal location\n* cSDH developed due to underlying condition\n* Life expectancy of \\\u003C1 year\n* Presents with an intracranial mass other than subdural hematoma\n* Presents with a meningioma with mass effect and\u002For ≥1 cm or currently undergoing radiation therapy for carcinoma or sarcoma of the head or neck region\n* Serum creatinine level \\> 3.0 mg\u002FdL at time of enrollment and not on dialysis\n* Life-threatening allergy to radiographic contrast (unless treatment for allergy is tolerated or can be managed medically)\n* Currently enrolled in another investigational study protocol that could potentially confound the interpretation of the study endpoints\u002Foutcomes\n* Known dangerous anatomic variations leading to increased procedural risk or unsafe access for MMAE\n* Contraindicated for the use of PHIL™ liquid embolic system","22 Years",{"count":57,"type":20},475,[23],"This is a prospective, randomized, controlled, open-label, blinded endpoint (PROBE) clinical investigation in which patients with non-emergent chronic subdural hematoma (cSDH) requiring treatment will be randomized (1:1) to either initial surgical evacuation (Control Arm) or initial MMAE with PHIL™ (investigational arm).",[61],"Chronic Subdural Hematomas","2026-05-04",{"date":64,"type":39},"2026-05-08",{"date":66,"type":20},"2026-12-31",{"date":68,"type":20},"2031-05-31",{"name":45,"class":46},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100554080","microvention-aneurysm--stroke-real-life-data-collection-100554080","NCT06494436","Microvention AnEurysm & STroke Real-life Data cOllection","Microvention Aneurysm & Stroke Real-life Data Collection","MAESTRO","Inclusion criteria:\n\n* Patient, or another authorized person as per country-specific regulations, is informed of the data collection and gives non-opposition or consent prior to the data collection in accordance with institutional and geographic requirements.\n* For Cohort 1, patient is treated for a ruptured or unruptured intracranial aneurysm using a commercially available MicroVention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.\n* For Cohort 2, patient is treated using a commercially available MicroVention mechanical thrombectomy device as the first-line treatment strategy and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.\n\nNote: For the purposes of this protocol, ancillary\u002Faccessory devices such as balloon catheters, carotid stent for extracranial stenosis and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices.\n\nExclusion Criteria:\n\n* Patient is or is expected to be inaccessible for follow-up.\n* Patient is participating or intends to participate in another study that changes the site practice.\n* Patient is already participating in the MAESTRO study for the same pathology.",{"count":79,"type":20},1000,"18 Months","OBSERVATIONAL","The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry",[84,85,86,87,26],"Intracranial Aneurysm","Intracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm Lesion","Aneurysmal Subarachnoid Hemorrhage","Ischemic Stroke",[89,90,91,92,93,94,95,96,97,98,32,99,100,101],"endovascular treatment","stent","flow diverter","hydrocoil","coil","implantable device","FRED","LVIS","WEB","Mechanical Thrombectomy","SOFIA","ERIC","BOBBY","RECRUITING","2026-02-05",{"date":105,"type":39},"2026-02-09",{"date":107,"type":39},"2024-12-30",{"date":109,"type":20},"2030-06-30",{"name":45,"class":46},1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":95,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100591619","fred-retrospective-study-of-intracranial-aneurysms-treatment-100591619","NCT06982781","FRED Retrospective Study of Intracranial Aneurysms Treatment","A Retrospective Post-Market Clinical Study of the Flow Re-Direction Endoluminal Device System in the Treatment of Intracranial Aneurysms","Inclusion Criteria:\n\n* People in China mainland who have been treated with FRED. The patients for whom clinical data are available\n\nExclusion Criteria:\n\n* Patients who met the inclusion criteria at all time points were required to be included in the study. Therefore, no specific exclusion criteria were set.","90 Years",{"count":121,"type":20},2000,"To evaluate the long-term safety and efficacy of Flow Re-Direction Endoluminal Device System (FRED) in the treatment of intracranial aneurysms in the post-market environment",[84],[125],"Intracranial Aneurysms","2025-05-20",{"date":128,"type":39},"2025-05-21",{"date":130,"type":20},"2025-05",{"date":132,"type":20},"2027-05-06",{"name":45,"class":46},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":111},"100555373","european-multi-center-exploratory-trial-to-assess-web-versus-other-endovascular-treatment-in-ruptured-aneurysms-100555373","NCT06511245","European, Multi-center, Exploratory Trial to Assess WEB Versus Other Endovascular Treatment in Ruptured Aneurysms.","WEB™ Embolization System in the Treatment of Acutely Ruptured Intracranial Aneurysms Versus Other Endovascular Techniques","WAVE","Main Inclusion Criteria:\n\n* Patient is above 18 years of age at the time of consent\n* Patient has an identified acutely ruptured intracranial aneurysm requiring endovascular treatment (for the purposes of this study an acutely ruptured IA patient is defined as a patient with computed tomography (CT), magnetic resonance imaging (MRI), or lumbar puncture (LP) evidence of subarachnoid hemorrhage attributed to the index aneurysm within the last 30 days)\n* Aneurysm dome diameter must be ≤ 10mm and within the diameter (and parent vessel diameter, as appropriate) range treatable by commercially available WEB devices as well as at least one other alternative commercially available endovascular treatment device used per hospital standard practice\n* Aneurysm is located on the anterior communicating artery complex segment (ACom), internal carotid artery terminus (ICAt), anterior cerebral artery (ACA), middle cerebral artery (MCA), basilar apex, posterior communicating artery (PCom) or pericallosal artery\n* Patient must be neurologically stable with a Hunt \\& Hess score of I to III\n* Patient or patient's legally authorized representative (LAR) has provided written informed consent\n\nMain Exclusion Criteria:\n\n* Aneurysm to be treated is unsuitable for endovascular treatment with commercially available WEB devices and\u002For all other available endovascular treatment techniques used per standard site practice\n* Patient presenting as target aneurysm a blister like or dissecting aneurysm\n* Patient has more than one aneurysm requiring treatment within 30 days of completion of treatment of the target aneurysm\n* Patient with multiple aneurysms in whom ruptured aneurysm cannot be identified\n* Patient has pre-morbid mRS \\> 2",{"count":143,"type":20},80,[23],"Comparison of efficacy and safety between WEB and other endovascular techniques",[147],"Ruptured Aneurysm","2024-12-13",{"date":150,"type":39},"2024-12-18",{"date":152,"type":39},"2024-10-02",{"date":154,"type":20},"2027-06",{"name":45,"class":46},""]